- Home
- ADVM vs CNTB Comparison
ADVM vs CNTB Comparison
Compare ADVM & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- CNTB
- Stock Information
- Founded
- ADVM 2006
- CNTB 2012
- Country
- ADVM United States
- CNTB United States
- Employees
- ADVM N/A
- CNTB N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- ADVM Health Care
- CNTB Health Care
- Exchange
- ADVM Nasdaq
- CNTB Nasdaq
- Market Cap
- ADVM 47.4M
- CNTB 54.4M
- IPO Year
- ADVM 2014
- CNTB 2021
- Fundamental
- Price
- ADVM $2.39
- CNTB $2.10
- Analyst Decision
- ADVM Strong Buy
- CNTB Strong Buy
- Analyst Count
- ADVM 5
- CNTB 2
- Target Price
- ADVM $23.80
- CNTB $7.50
- AVG Volume (30 Days)
- ADVM 133.0K
- CNTB 274.7K
- Earning Date
- ADVM 08-11-2025
- CNTB 09-04-2025
- Dividend Yield
- ADVM N/A
- CNTB N/A
- EPS Growth
- ADVM N/A
- CNTB N/A
- EPS
- ADVM N/A
- CNTB N/A
- Revenue
- ADVM $1,000,000.00
- CNTB $26,033,000.00
- Revenue This Year
- ADVM N/A
- CNTB N/A
- Revenue Next Year
- ADVM $18.82
- CNTB N/A
- P/E Ratio
- ADVM N/A
- CNTB N/A
- Revenue Growth
- ADVM N/A
- CNTB N/A
- 52 Week Low
- ADVM $1.78
- CNTB $0.51
- 52 Week High
- ADVM $8.56
- CNTB $2.86
- Technical
- Relative Strength Index (RSI)
- ADVM 42.53
- CNTB 62.23
- Support Level
- ADVM $2.61
- CNTB $1.70
- Resistance Level
- ADVM $2.82
- CNTB $2.45
- Average True Range (ATR)
- ADVM 0.21
- CNTB 0.37
- MACD
- ADVM -0.02
- CNTB 0.01
- Stochastic Oscillator
- ADVM 3.20
- CNTB 56.70
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.